SCHEMBL2327770

SCHEMBL2327770

CN1CC2CN(c3ccc(-c4ccccc4)nn3)CC(C1)O2

nearest known ligand 0.72

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 6/20 0.72
HTR3A P46098 1/20 0.72
CHRNB4 P30926 1/20 0.72
CHRNA3 P32297 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333298 0.86 CHRNA7 (0.54) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL29366074 0.84 CHRNA7 (1.00) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL29422976 0.84 CHRNA7 (1.00) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL676044 0.84 CHRNA7 (1.00) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL14479461 0.84 CHRNA7 (1.00) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL18016312 0.84 CHRNA7 (1.00) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL2322822 0.83 CHRNA7 (0.72) CHRNA7HTR3ACHRNB4CHRNA3
Hydrochloric Acid SCHEMBL6322692 0.83 CHRNA7 (0.97) CHRNA7HTR3ACHRNB4CHRNA3
Hydrochloric Acid SCHEMBL1790893 0.83 CHRNA7 (0.97) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL2331059 0.83 CHRNA7 (0.50) CHRNA7HTR3ACHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257168-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2011-10-20 US claimed
EP-2356125-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Targacept, Inc. (US) 2011-08-17 EP claimed
WO-2010002971-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-01-07 WO claimed
US-20110257168-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2011-10-20 US disclosed
EP-2356125-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Targacept, Inc. (US) 2011-08-17 EP disclosed
WO-2010002971-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257168-A1 DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA5, CHRNA2, CHRNB2 CHRNA7 5/4885HTR3A 351/4885CHRNB4 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.